Lupin Limited: Business Overview, Financials & Competitive Analysis
Lupin Limited scores 7/10 on the AskCyborg Cyborg Score (Strong). Established global generic pharma leader with ESG advantages, facing growth normalization but well-positioned in essential medicines across developed and emerging markets. Lupin demonstrates solid operational scale with $10.4B market cap and $2.81B trailing revenue, strong global diversification across 100+ markets, and industry-leading ESG credentials. However, the company faces headwinds with.
What is Lupin Limited's industry? Lupin Limited (lupin.com) operates in Pharmaceuticals - Global Generic & Specialty Drugs. AskCyborg classifies Lupin Limited under Pharmaceuticals - Global Generic & Specialty Drugs in its company registry.
Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai, primarily a manufacturer of generic drugs covering therapeutic areas such as paediatrics, cardiovascular, anti-infectives, diabetology, ...
Cyborg Score thesis
Established global generic pharma leader with ESG advantages, facing growth normalization but well-positioned in essential...
Read the full analyst-debate transcript →Get the Latest Lupin Limited Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeLupin Limited Overview
Pro stress-test →Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai, primarily a manufacturer of generic drugs covering therapeutic areas such as paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific, Latin America, Europe, and Middle East regions.
Strategic Profile
Pro stress-test →Lupin operates a highly diversified pharmaceutical business with a strong presence across key global markets, with operations spanning generics, complex formulations, branded products, and other high-burden specialty segments, supported by robust R&D and manufacturing capabilities. The company achieved an S&P Global ESG Score of 91, ranking as World No. 1 in sustainability in the pharmaceutical industry as of February 7, 2026.
Competitive Landscape
Pro stress-test →Lupin has a significant presence in Cardiovascular, Diabetology, Asthma, Pediatrics, and Central Nervous System segments, and is a global leader in Anti-TB and Cephalosporins segments. The company competes with major Indian pharma exporters and global generics manufacturers, maintaining the 5th largest and fastest growing position in the US generics market.
Industry Context
Lupin Limited operates in Pharmaceuticals - Global Generic & Specialty Drugs.
Key facts
Founded: 1968 · Headquarters: Mumbai, India · Revenue: $2.81B · Market cap: $10.4B